Marrow Transplantation for Chronic Myeloid Leukemia: The Influence of Plasma Busulfan Levels on the Outcome of Transplantation
Open Access
- 15 April 1997
- journal article
- Published by American Society of Hematology in Blood
- Vol. 89 (8), 3055-3060
- https://doi.org/10.1182/blood.v89.8.3055
Abstract
The influence of busulfan (BU) plasma concentration on outcome of transplantation from HLA identical family members for the treatment of chronic myelogenous leukemia (CML) was examined in 45 patients transplanted in chronic phase (CP) (n = 39) or accelerated phase (AP) (n = 6). All patients received the same regimen of BU, 16 mg/kg orally and cyclophosphamide (CY), 120 mg/kg intravenously. Plasma concentrations of BU at steady state (CSSBU) during the dosing interval were measured for each patient. The mean CSSBU was 917 ng/mL (range, 642 to 1,749; median, 917; standard deviation, 213). Of patients with CSSBU below the median, seven (five of 18 in CP and two of four in AP) developed persistent cytogenetic relapse and three of these patients died. There were no relapses in patients with CSSBU above the median. The difference in the cumulative incidence of relapse between the two groups was statistically significant (P = .0003). CSSBU was the only statistically significant determinant of relapse in univariable or multivariable analysis. The 3-year survival estimates were 0.82 and 0.64 for patients with CSSBU above and below the median (P = .33). There was no statistically significant association of CSSBU with survival or nonrelapse mortality, although the power to detect a difference in survival between 0.82 and 0.64 was only 0.24, similarly CSSBU above the median was not associated with an increased risk of severe regimen-related toxicity. We conclude that low BU plasma levels are associated with an increased risk of relapse.This publication has 24 references indexed in Scilit:
- Efficacy and Safety of Fluconazole Prophylaxis for Fungal Infections after Marrow Transplantation--A Prospective, Randomized, Double-Blind StudyThe Journal of Infectious Diseases, 1995
- Strategies for the Prevention of Cytomegalovirus Disease After Marrow TransplantationClinical Infectious Diseases, 1994
- Summarizing data on survival, relapse, and chronic graft‐versus‐host disease after bone marrow transplantation: motivation for and description of new methodsBritish Journal of Haematology, 1993
- A comparative study of HLA‐DRB1 typing by standard serology and hybridization of non‐radioactive sequence‐specific oligonucleotide probes to PCR‐amplified DNATissue Antigens, 1993
- Methotrexate and Cyclosporine Compared with Cyclosporine Alone for Prophylaxis of Acute Graft versus Host Disease after Marrow Transplantation for LeukemiaThe New England Journal of Medicine, 1986
- Bone Marrow Transplantation for Patients with Chronic Myeloid LeukemiaThe New England Journal of Medicine, 1986
- MARROW TRANSPLANTATION FOR PATIENTS IN THE CHRONIC PHASE OF CHRONIC GRANULOCYTIC LEUKAEMIAThe Lancet, 1982
- TREATMENT OF CHRONIC GRANULOCYTIC LEUKAEMIA IN CHRONIC PHASE BY ALLOGENEIC MARROW TRANSPLANTATIONThe Lancet, 1982
- SUCCESSFUL ALLOGENEIC BONE-MARROW TRANSPLANTATION FOR PATIENTS IN THE ACCELERATED PHASE OF CHRONIC GRANULOCYTIC LEUKAEMIAThe Lancet, 1982
- Nonparametric Estimation from Incomplete ObservationsJournal of the American Statistical Association, 1958